Take advantage of support offerings like:

  • A dedicated support team, including a Patient Resource Navigator and CSL Case Manager
  • Insurance assessment to investigate coverage and explain your benefits
  • Logistics and travel support
  • Determination of eligibility for financial assistance programs
  • Ongoing commitment to providing additional support and resources

Enroll today for support throughout your
treatment journey with HEMGENIX

Patient Information

All fields with an asterisk are required.

Are you 18 or over and living with hemophilia B?*

Thank you for your interest in HEMGENIX!

Enrollment in HEMGENIX Connect is only available to people 18 years of age or over and living with hemophilia B.

Which number do you prefer we contact?*


These initials denote that I authorize HEMGENIX ConnectSM to leave information regarding my HEMGENIX prescription, insurance coverage, and Specialty Pharmacy Provider on my voicemail or alternate contact (participation optional).

These initials denote that I authorize CSL Behring, HEMGENIX Connect, and its other service providers to send me autodialed and prerecorded marketing calls and text messages at the telephone number(s) that I provide. I understand that I may opt-out of autodialed and prerecorded marketing calls and text messages at any time through the means by which I have been contacted (participation optional).

These initials denote that I authorize HEMGENIX Connect to leave information regarding my HEMGENIX prescription, insurance coverage, and health information to the following individual (participation optional).

To help your CSL Case Manager conduct a benefits investigation for HEMGENIX, please select your type of insurance and fill out the corresponding section of the form below*:

If you are enrolled in a private, non-governmental insurance plan (such as an employer-sponsored plan, including FEHB program, or plans from the healthcare marketplace), please attach a photo of the front and back of your insurance card OR fill out the section below:

Please either attach a photo of the front and back of your insurance card OR fill out the section below

Thank you for enrolling!

Welcome! We will reach out to you soon to introduce our team and the kinds of support you can expect.

Server Error!

We’re sorry for the inconvenience; please try signing up again later!

Amelia
Virtual Assistant
Hello, I am Amelia. How can I help you today? If this is a medical emergency, please call 911 or report to your local emergency room.
toggle chat overlay toggle chat overlay
Top of Page

IMPORTANT SAFETY INFORMATION

Before you can receive HEMGENIX®, etranacogene dezaparvovec-drlb, your doctor will perform tests to check for Factor IX inhibitors. If you have inhibitors, or have had them in the past, you are not a candidate for HEMGENIX. Your doctor will also check your liver health and screen for hepatitis B and C, as active infection may affect how well the treatment works or increase the risk of side effects.

Infusion-related and allergic reactions (including anaphylaxis) can occur. You will be monitored throughout infusion and for at least 3 hours afterward. If a reaction occurs during infusion, the infusion may be slowed or interrupted as symptoms are addressed, then started at a slower rate once symptoms have resolved.

Liver effects including liver injury can occur. Your doctor will monitor your liver with blood tests every week for 3 months and then monthly up to 1 year after treatment. Increased liver enzymes may require corticosteroid treatment. Because HEMGENIX works in the liver, there is a potential (possible but not proven) risk of liver cancer, and some patients may be monitored for up to 5 years.

After treatment, your body will develop antibodies to HEMGENIX, which may affect how well it works.

Your doctor will monitor Factor IX levels and check for inhibitors. You may still need support to help control bleeding, especially in the initial weeks after treatment.

Most common side effects include increased liver enzymes, headache, increased blood creatine kinase, flu-like symptoms, infusion-related reactions, fatigue, nausea, and feeling unwell. These are not the only side effects possible. Tell your healthcare provider about any side effect you may experience.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You can also report side effects to CSL Behring’s Pharmacovigilance Department at 1-866-915-6958.

INDICATION

HEMGENIX is indicated for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who:

  • Currently use Factor IX prophylaxis therapy, or
  • Have current or historical life-threatening hemorrhage, or
  • Have repeated, serious spontaneous bleeding episodes.

Please see full prescribing information for HEMGENIX.

You are now leaving the current website.

The site you are accessing is maintained by a third party over whom CSL Behring has no control. CSL Behring does not review, approve, or necessarily endorse viewpoints, inferences, or conclusions stated in or implied by the content of this site. CSL Behring is not responsible for third-party content or the consequences of your use thereof.

Do you want to continue?

Your enrollment request hasn’t been submitted

Are you sure you want to leave? Any progress will not be saved.